Atai Beckley N.V(ATAI)Earnings, Financials & Key RatiosAtai Beckley N.V (ATAI) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's rapid cash burn, which reduced the cash balance by nearly 50% to $43.1 million in a single quarter, suggests significant dilution risk for shareholders as the firm attempts to fund its clinical pipeline.
Atai Beckley N.V (ATAI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Atai Beckley N.V (ATAI) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.08vs $0.11+27.3% | $954,000vs $217,111+339.4% |
| Q2 2026 | Mar 6, 2026 | $0.05vs $0.12+58.3% | $1Mvs $300,000+255.3% |
| Q4 2025 | Nov 12, 2025 | $0.28vs $0.12-133.3% | $749,000vs $229,170+226.8% |
| Q3 2025 | Aug 14, 2025 | $0.14vs $0.12-16.7% | $719,000 |
Recent stock market news and headlines for Atai Beckley N.V (ATAI)
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced on Thursday that it will be added to the Russell 2000 Index and the Russell 3000 Index, effective at the open of US markets on June 29, as part of the 2026 Russell indexes reconstitution. The clinical-stage biotechnology company said the inclusion broadens its exposure to institutional investors and index-tracking funds.
Blackberry (TSX:BB) shares jumped nearly 21% on Thursday in New York and Toronto after the Canadian technology company posted first-quarter fiscal 2027...
AtaiBeckley to be added to the Russell 2000® Index and the broad-market Russell 3000® Index as part of 2026 reconstitution The Russell U.S. Indexes have approximately $12.2 trillion in assets benchmarked Inclusion expands AtaiBeckley's visibility across U.S. equity markets following recent additions to the S&P Total Market Index, S&P Completion Index, and CRSP® U.S. benchmark indexes in March 2026 NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that it will be added to the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. markets on June 29th as part of the first 2026 Russell indexes reconstitution. Approximately $12.2 trillion in assets are benchmarked against the Russell U.S. indexes, making it one of the most widely referenced index systems for institutional investors, index-tracking funds and active investment strategies.
Key metrics vs top competitors for Atai Beckley N.V (ATAI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.19 | $1.91B | -1.78 | 1227.6% | -16142.02% | -389.92% | — | |
| $12.99 | $1.25B | -4.22 | — | — | -151.02% | — | |
| $20.69 | $2.04B | -10.04 | — | — | -102.48% | — | |
| $6.09 | $303.86M | -13.66 | — | — | -81% | — | |
| $5.66 | $5.12M | -0.75 | — | -6717.4% | -88.41% | — | |
| $1.45 | $865.67K | -0.04 | — | — | -220.99% | — |
Atai Beckley N.V (ATAI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Atai Beckley N.V (ATAI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Dec 5, 2025·SEC
Nov 12, 2025·SEC
Nov 5, 2025·SEC
Get notified when ATAI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Atai Beckley N.V (ATAI) stock FAQ — growth, dividends, profitability & financials explained
Atai Beckley N.V (ATAI) reported $3.5M in revenue for fiscal year 2025.
Atai Beckley N.V (ATAI) grew revenue by 1227.6% over the past year. This is strong growth.
Atai Beckley N.V (ATAI) reported a net loss of $663.4M for fiscal year 2025.
Atai Beckley N.V (ATAI) has a return on equity (ROE) of -389.9%. Negative ROE indicates the company is unprofitable.
Atai Beckley N.V (ATAI) had negative free cash flow of $117.2M in fiscal year 2025, likely due to heavy capital investments.
